Trametinib as second-line therapy for advanced KRAS G12C-mutant non-small cell lung cancer: a single-center clinical analysis of 20 cases - Quiz - MDSpire

Trametinib as second-line therapy for advanced KRAS G12C-mutant non-small cell lung cancer: a single-center clinical analysis of 20 cases

  • By

  • Xinhui Wang

  • Junyan Yu

  • May 28, 2026

  • 0 min

Share

Original Source(s)

Trametinib as second-line therapy for advanced KRAS G12C-mutant non-small cell lung cancer: a single-center clinical analysis of 20 cases

  • by Xinhui Wang, Junyan Yu

  • May 28, 2026

Related Content

Biotech exec Jeremy Levin on the industry’s strategic turning point

Potential targets for boron transport in boron neutron capture therapy

Novel approaches for separating graft-versus-leukemia effects from graft-versus-host disease